L&G Pharma Breakthrough UCITS ETF

ETF (UCITS compliant)
L&G Pharma Breakthrough UCITS ETF
USD Accumulating ETF Class
Fund aim
The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").
Fund snapshot
- Long-term allocation
Long-term value in a pharmaceutical sub-sector that benefits from certain commercial and regulatory incentives
- High growth potential
Aims to capture the future growth opportunity in orphan drugs
- Leveraging industry expertise
An index tracking investment strategy that is supported by a team of pharmaceutical experts
- Does it have a sustainable objective?
The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.
Fund facts
| Fund size | |
| Base currency | USD |
| Fund launch date | 15 Dec 2017 |
| Share class launch | 23 Jan 2018 |
| Domicile | Ireland |
| Replication method | Physical - full replication |
Benchmark
Solactive Pharma Breakthrough Value Index
Index description
Solactive Pharma Breakthrough Value Index Net TR USD
The Index is comprised of bio-technology companies which are publicly traded on various stock exchanges around the world that are actively engaged in the research, development and manufacture of orphan drugs. An “orphan drug” is a pharmaceutical product that has been developed specifically to treat rare diseases or disorders. A company is only eligible for inclusion in the Index if (1) it is of a sufficient size (determined by reference to the total market value of the proportion of its shares that are publicly traded) and (2) it is sufficiently “liquid” (a measure of how actively its shares are traded on a daily basis).
The universe of companies out of which the Index selection is made is refreshed annually in April. However, the Index is reconstituted semi-annually in April and October in accordance with the full selection criteria and all companies are equally weighted within the Index. On a monthly basis, the weight of each company is assessed and, if any of them exceeds 15% of the Index, the weights of all companies are adjusted so that they are again equally weighted within the Index.
Index data
| Provider | Solactive |
| Bloomberg code | SOLBIOT |
| Reuters code | .SOLBIOT |
| Type | Net Total Return |
| Website | Go to website |
Performance
Performance scenarios
Example investment: 10,000 USD
Portfolio breakdown
As at 30 Sep 2026
| Top 10 constituents | 27.0% |
|---|---|
| Rest of Index | 73.0% |
| Number of constituents in Index | 41 |
|---|
Top 10 constituents (%)
| Xeris Biopharma | 2.9 |
| United Therapeutics | 2.9 |
| Ligand Pharmaceuticals | 2.8 |
| Basilea Pharmaceutica Ltd | 2.7 |
| Genmab A/S | 2.7 |
| Eisai | 2.6 |
| Biogen Inc | 2.6 |
| Beone Medicines | 2.6 |
| AstraZeneca | 2.6 |
| Agios Pharmaceuticals | 2.6 |
Sector (%)
Health Care | 97.7 |
Materials | 2.3 |
| Top 10 constituents | 27.0% |
|---|---|
| Rest of Index | 73.0% |
| Number of constituents in Index | 41 |
|---|
Top 10 constituents (%)
| Xeris Biopharma | 2.9 |
| United Therapeutics | 2.9 |
| Ligand Pharmaceuticals | 2.8 |
| Basilea Pharmaceutica Ltd | 2.7 |
| Genmab A/S | 2.7 |
| Eisai | 2.6 |
| Biogen Inc | 2.6 |
| Beone Medicines | 2.6 |
| AstraZeneca | 2.6 |
| Agios Pharmaceuticals | 2.6 |
Sector (%)
Health Care | 97.7 |
Materials | 2.3 |
Currency (%)
USD | 68.0 |
JPY | 9.9 |
EUR | 6.9 |
CHF | 2.7 |
DKK | 2.7 |
GBP | 2.6 |
HKD | 2.5 |
SEK | 2.4 |
KRW | 2.3 |
Country (%)
United States | 60.8 |
Japan | 9.9 |
United Kingdom | 4.9 |
Switzerland | 2.7 |
Denmark | 2.7 |
Italy | 2.5 |
Cayman Islands | 2.5 |
Ireland | 2.4 |
Sweden | 2.4 |
Other | 9.0 |
All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding. The breakdowns shown relate to the Index. The ETF’s portfolio may deviate from the portfolio of the Index.
Fund managers

L&G Index Fund Management Team
The skill set and expertise we have developed over 35+ years in index management has allowed us to continuously evolve our investment processes. The Index Fund Management team comprises 30 fund managers with an average experience of 15 years, supported by 33 broader team members. Management oversight is provided by Dave Barron, Global Head of Index, ETFs & Systematic Solutions. The team also has full access to the resources and research of other specialists within L&G, including economists and strategists.
SFDR categorisation
Article 9
The sustainable investment objective of the Fund is to provide exposure to the global orphan drugs industry. The Fund and seeks to achieve its investment objective by tracking the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.
The sustainable investment objective of the Fund is to provide exposure to the global orphan drugs industry. The Fund and seeks to achieve its investment objective by tracking the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.
The Fund follows the following sustainability-related investment strategy by tracking the Index that applies:
Literature
Document type
Prices
Pricing information
| Price time | 16:00 EST (NY) |
| Currency | USD |
Listings and codes
Listings
| Exchange | Currency | Ticker | ISIN | Bloomberg | WKN | Reuters | Listing date | Trading hours (local) |
|---|---|---|---|---|---|---|---|---|
| London Stock Exchange | GBP | BIGT | IE00BF0H7608 | BIGT LN | A2H9XR | BIGT.L | 23/01/2018 | 08:00 - 16:30 |
| London Stock Exchange | USD | BIOT | IE00BF0H7608 | BIOT LN | A2H9XR | GEBIOT.L | 23/01/2018 | 08:00 - 16:30 |
| Borsa Italiana | EUR | BIOT | IE00BF0H7608 | BIOT IM | A2H9XR | ECBIOT.MI | 23/02/2018 | 09:00 - 17:30 |
| Deutsche Börse Xetra | EUR | ETLI | IE00BF0H7608 | ETLI GY | A2H9XR | ETLI.DE | 06/02/2018 | 09:00 - 17:30 |
| Euronext Amsterdam | EUR | BIOT | IE00BF0H7608 | BIOT NA | A2H9XR | GOBIOT.AS | 01/02/2018 | 09:00 - 17:30 |
| SIX Swiss Exchange | CHF | BIOT | IE00BF0H7608 | BIOT SW | A2H9XR | BIOTC.S | 05/06/2020 | 09:00 - 17:30 |
Share class codes
| ISIN | IE00BF0H7608 |
| SEDOL | BF0H760 |
| Bloomberg | BIOT |
| WKN | A2H9XR |
Dealing information
| Issuer | Legal & General UCITS ETF Plc |
| Depositary and Trustee | The Bank of New York Mellon SA/NV, Dublin Branch |
| Securities regulator | Central Bank of Ireland |
Country registration
This share class is registered for sale in the following countries:




















